Understanding and mitigating cancer-related financial toxicity in China: challenges and recommendations
Cancer imposes a substantial financial burden on patients worldwide, and China is no exception. As the country faces a rising cancer incidence and improving survival rates, financial toxicity—the objective financial burden and subjective distress caused by the cost of cancer treatment and care—has emerged as a critical but under-addressed issue in oncology. China's unique healthcare, insurance, and cultural context presents challenges to financial toxicity that differ from those seen elsewhere in the world.
Authors
- Yuhan Lu (ORCID: https://orcid.org/0000-0003-3752-8354)
- Juan Xie (ORCID: https://orcid.org/0000-0002-4170-9273)
- Weijie Xing (ORCID: https://orcid.org/0000-0002-1327-1059)
- Huiying Qin
- Qinyi Guan (ORCID: https://orcid.org/0009-0000-0858-8986)
- Z. John Lu
Institutions
- Sun Yat-sen University (CN)
- Shanxi Medical University (CN)
- Peking University (CN)
- Fudan University (CN)
- Kunming Medical University (CN)
- Shaanxi Provincial People's Hospital (CN)
- Fudan University Shanghai Cancer Center (CN)
- Peking University Cancer Hospital (CN)
- Sun Yat-sen University Cancer Center (CN)
- Shanxi Provincial People’s Hospital (CN)
Publication Details
- Journal
- The Lancet Regional Health - Western Pacific
- Published
- 2025-06-17
- DOI
- https://doi.org/10.1016/j.lanwpc.2025.101601
- Citations
- 3
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 9.39
Funders
- China Medical Board
- National Natural Science Foundation of China